Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259492 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
A Phase 3 study of Attention Deficit/Hyperactivity Disorder, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 725
- Enrollment target
- 20
- Study locations
NCT01259492 is a Phase 3 study of Attention Deficit/Hyperactivity Disorder that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 725 participants, above the 244-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (197% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT01259492, a Phase 3 study of Attention Deficit/Hyperactivity Disorder, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 725 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ritalin LA 20 mg
- DRUG Ritalin LA 30 mg
Study Locations (20)
Florida
- Novartis Investigative Site - Bradenton
- Novartis Investigative Site - Miami
- Novartis Investigative Site - Orlando
- Novartis Investigative Site - West Plam Beach
California
- Novartis Investigative Site - Beverly Hills
- Novartis Investigative Site - Spring Valley
Nevada
- Novartis Investigative Site - Las Vegas
- Novartis Investigative Site - Las Vegas
Texas
- Novartis Investigative Site - Houston
- Novartis Investigative Site - Houston
Arkansas
- Novartis Investigative Site - Little Rock
Illinois
- Novartis Investigative Site - Libertyville
Kentucky
- Novartis Investigative Site - Owensboro
Michigan
- Novartis Investigative Site - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 725 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01259492
The ClinicalTrials.gov registry entry for NCT01259492 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 725 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 244-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (197% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit/Hyperactivity Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01259492 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Nevada.
Frequently Asked Questions
What is clinical trial NCT01259492 about?
NCT01259492 is a clinical study titled "Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)". This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
What is the current status of trial NCT01259492?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 725 participants. The study started on 2010-11. Estimated completion is 2012-08.
What conditions does trial NCT01259492 study?
This clinical trial studies the following conditions: Attention Deficit/Hyperactivity Disorder.
What interventions are being tested in trial NCT01259492?
The interventions under investigation include: Placebo (DRUG), Ritalin LA 20 mg (DRUG), Ritalin LA 30 mg (DRUG).
Who is sponsoring clinical trial NCT01259492?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01259492 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit/Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
ACTIVE NOT RECRUITING · Phase 3
-
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
ACTIVE NOT RECRUITING · Phase 3
-
Focus Groups in Ethnically and Racially Diverse Families
RECRUITING
-
Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
RECRUITING · NA
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.